Compare DraftKings Inc (DKNG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Sanofi SA — how do they compare? DraftKings Inc trades at $25.18 (market cap $12.58B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 8.3× DraftKings Inc's market cap, and Sanofi SA pays a 5.55% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | SNY | |
|---|---|---|
Market Cap | $12.58B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $52.34 |
52-Week Low | $20.72 | $41.33 |
Enterprise Value | $13.51B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $24.27, up 1.0% today, showing mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company achieved its first annual net profit in 2025 ($4M) after years of losses, with revenue growing to $6.05B. However, recent quarterly earnings have missed expectations, and valuation ratios remain elevated with a P/E of 246.33. Analyst sentiment remains positive with 73% buy ratings and a $34 consensus price target, representing 40% upside potential.
The outlook for DKNG hinges on successful execution in prediction markets and sportsbook growth, particularly with the upcoming NFL season. Key risks include intense competition from prediction market platforms, regulatory challenges, and the company's ability to maintain profitability after recently turning profitable. While technical indicators show near-term resistance at $25, the substantial analyst upside and improving cash flow trends suggest potential for long-term growth if execution improves.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
